Cancer genome engineering laboratory
Basic/translational research
Vall d'Hebron Institute of Oncology (VHIO)
·Barcelona ·

Our group studies the role of large-scale chromosomal changes known as copy number alterations (CNA) in pancreatic ductal adenocarcinoma (PDAC). We combine state-of-the-art genomic engineering strategies with in vivo models of PDAC to uncover the mechanisms by which NACs enable cancer cells to spread and resist therapies.

We are particularly interested in the role of these alterations in immune surveillance, tumor heterogeneity and cancer genome evolution. Our long-term goal is to understand the complex biology of CNAs to identify new therapeutic strategies that target PDAC cells with these chromosomal aberrations.

Main publications in pancreatic cancer:

  1. Barriga FM, Tsanov KM, Ho YJ, et al. MACHETE identifies interferon-encompassing chromosome 9p21.3 deletions as mediators of immune evasion and metastasis. Nature Cancer. 2022; 3(11): 1367-1385.
  2. Alonso-Curbelo D, Ho YJ, Burdziak C, et al. A gene-environment-induced epigenetic program initiates tumorigenesis. Nature. 2021; 590(7847): 642-648.
Francisco Barriga

Principal Investigator

Group members

  • Group Leader – Francisco M. Barriga, PhD
  • Lab Manager – Xieng Chen Wang, MSc
  • Technician – Golsa Jahangiri, MSc
  • Postdoc – Dario Ruiz, PhD
  • Postdoc – Elisa Pérez, PhD
  • PhD Student – Matea Katić, MSc
  • PhD Student – Sofia Calpe, MSc
  • PhD Student – Claudia Yáñez, MSc

Other groups